Pressrelease
March 28, 2013
Due to the large interest in investing in Immunicum that has been shown, on March
28, 2013, the Board of Directors of the Company decided to conduct a private
placement to professional investors bringing in 8,8 million SEK. This was announced
in the Company's investment memorandum for the recent listing’s issuance of 21,4
million SEK. The largest of these professional investors is LMK Forward AB.
Immunicums CEO, Jamal El-Mosleh said:
"We are happy to see that larger professional investors are showing confidence in
the technologies that Immunicum is working with. The extra financing will be able to
contribute to an increased pace in the planning of the upcoming clinical phase II-trial
in renal cancer."
G&W Kapitalförvaltning acted as financial advisor and has been selected as
Immunicum’s Certified Adviser for the Company's upcoming listing on NASDAQ OMX
First North. Preliminary first day of trading is April 22:nd.
For further information see Immunicums website: www.immunicum.se or contact
Jamal El-Mosleh, CEO Immunicum AB, tel: 031-772 81 50, 0703-31 90 51.
Email: jamal.el-mosleh@immunicum.com.
About Immunicum AB (publ):
Immunicum AB (publ) develops cancer immunotherapies. Its two main groups of
therapeutic cancer vaccines, SUBCUVAX™ and INTUVAX™, and the method of
expansion of tumor-specific T-cells (CD70) is based on the Nobel prize awarded
discovery of the dendritic cell and its central role in the activation of the specific
immune response. Because the raw material consists of dendritic cells from healthy
donors, Immunicum’s products can be produced in large scale. The vaccines have
proven efficacy in animal studies and are now undergoing tests on patients.
